ASPEN Rhoads Research Foundation Report issue

Foundation Phase 3

Organization Overview

First Clinical Trial
2005
NCT00586807
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

ASPEN Rhoads Research Foundation

Active Ingredients

Drugs in Phase 3 Trials (2)

fish oil (Omegavan) (1 trial)

soybean oil (Intralipid) (1 trial)

Drugs in Other Trials (1)

amino acids (Freamine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cholestasis (Phase 3)

Liver Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3